• Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting continued late-stage development.
• 6-minute walk distance rose about 55 meters from baseline in both TPIP-continued and placebo-crossed groups; NT-proBNP fell about 60%.
• About 65% of patients reached refined low-risk status on REVEAL Lite 2.0 by month 12; scores improved 2 points or 1.4 points.
• Safety profile stayed consistent through month 12 with no new signals; 7.7% discontinued; four deaths were reported, none treatment-related.
• Phase 3 PALM-PAH started; primary endpoint is change in 6-minute walk distance over 24 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160700PR_NEWS_USPR_____NY05956) on July 16, 2026, and is solely responsible for the information contained therein.